HeartX Cardiovascular Accelerator Announces Five Startup Companies Selected for the 2026 Program

FAYETTEVILLE, Ark., Sept. 28, 2026 /PRNewswire/ -- HeartX, powered by HTA and MedAxiom — along with leading cardiovascular programs across the country — has selected five startup healthcare companies to participate in the 2026 accelerator program.

HeartX is a cardiovascular-focused healthcare accelerator that connects accomplished, early-stage companies with cardiovascular providers to facilitate pilot projects and clinical studies designed to validate innovative technologies in real-world care settings. Each company selected for the 2026 cohort will receive $150,000 in investment capital and is guaranteed at least one pilot project or clinical study with a participating cardiovascular program.

The five companies selected for the 2026 HeartX program are:

Flow Medical — Chicago, Illinois, USA
Flow Medical is developing technology to advance the treatment of pulmonary embolism through a personalized approach to catheter-directed thrombolysis. Its all-in-one angiography, infusion and monitoring catheter provides physicians with real-time feedback on clot resolution.

Mode Sensors — Trondheim, Norway
Mode Sensors develops wearable technology for continuous, non-invasive fluid monitoring. Its ReBalans® system uses advanced biosensors to provide real-time information about a patient's fluid status.

Noah Labs — Berlin, Germany
Noah Labs develops AI-powered technology for remote monitoring and earlier detection of worsening heart failure. Its platform combines telemonitoring with Noah Labs Vox™, an AI-based voice analysis technology designed to detect signs of cardiac decompensation before hospitalization.

Galenband — Galway, Ireland
Galenband is developing a wearable cardiac telemetry system designed to continuously monitor cardiac function for up to 90 days. The system combines medical-grade sensors with automated data transmission and AI-supported analysis to help clinicians identify cardiac abnormalities while providing patients with a non-invasive alternative to implantable monitoring devices.

Omini — Suresnes, France
Omini is developing a point-of-care blood biomarker monitoring platform for patients with chronic diseases. Its portable system uses multiplex electrochemical biosensor technology to measure multiple blood biomarkers from a single capillary blood sample, providing clinicians with information that can support therapy adjustments and ongoing disease management.

"The companies selected for this year's HeartX cohort are tackling some of the most persistent challenges in cardiovascular care — from identifying deterioration sooner to giving clinicians better information to personalize treatment," said Jeff Stinson, director of HTA. "What makes HeartX unique is the opportunity to move those technologies into direct collaboration with our providers. We're excited to see what these five companies can accomplish with access to HeartX clinicians, patients and real-world care settings."

"Meaningful innovation happens when emerging technologies are developed alongside the clinicians and organizations that will ultimately use them," said Joe Sasson, PhD, MedAxiom's chief commercial officer and executive vice president of Ventures. "The 2026 HeartX cohort brings together solutions addressing a diverse range of cardiovascular challenges. We look forward to helping these companies gain the clinical insights, relationships and validation they need to advance their technologies and their impact on patient care."

Representatives from participating cardiovascular programs across the country, HTA and MedAxiom, evaluated applicants and selected companies with technologies that have the potential to advance cardiovascular innovation and care.

The 2026 HeartX program will kick off at MedAxiom's CV Transforum conference in Denver, Colorado, Oct. 22-24.

More information about HeartX can be found at HeartXAccelerator.com.

ABOUT HEALTHTECH ARKANSAS
HTA helps to drive innovation for healthcare provider organizations and clinical engagement for startup companies. Its flagship accelerator, HeartX, recruits worldwide for the most accomplished cardiovascular-focused startups in the areas of digital health, medical devices, and diagnostics. Those companies accepted into the program are guaranteed facilitated hospital pilot projects and clinical trials with leading cardiology practices around the country, along with financial investment, mentoring and exposure to the HeartX network. More information can be found at HealthTechArkansas.com.

ABOUT MEDAXIOM
MedAxiom, an American College of Cardiology Company, is the cardiovascular community's premier source for organizational performance solutions. MedAxiom is transforming cardiovascular care by combining the knowledge and power of hundreds of cardiovascular organization members, thousands of administrators, clinicians and revenue cycle experts, and dozens of industry partners. Through the delivery of proprietary tools, smart data and proven strategies, MedAxiom helps cardiovascular organizations achieve the Quadruple Aim of better outcomes, lower costs, improved patient experience and improved clinician experience. Learn more at MedAxiom.com.

For more information, contact:
Jeff Stinson
501.766.0633
[email protected] 

SOURCE HTA